Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT

Patrice Dubreuil, Sébastien Letard, Marco A. Ciufolini, +14

PLoS ONE

Mechanisms of STAT Protein Activation by Oncogenic KIT Mutants in Neoplastic Mast Cells

Amandine Chaix, Sophie Lopez, Edwige Voisset, +3

Journal of Biological Chemistry

Mast Cell DisorderImmunologyCell ProliferationStat3 DownstreamSignaling Pathway +15

Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice

Edwige Voisset, Eva Moravcsik, Eva W. Stratford, +7

Blood

The tyrosine kinase FES is an essential effector of KITD816V proliferation signal

Edwige Voisset, Sophie Lopez, Patrice Dubreuil, +1

Blood

An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia

Sophie Lopez, Edwige Voisset, Julie Tisserand, +5

Oncotarget

FES kinases are required for oncogenic FLT3 signaling

Edwige Voisset, Sophie Lopez, A Chaix, +5

Leukemia

Signal TransductionSignaling PathwayCell RegulationReceptor Tyrosine KinaseGene Expression +4

The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia

Jelena Jovanović, Carmen Chillón, Christelle Vincent‐Fabert, +11

Leukemia

Hematological MalignancyMixed-phenotype Acute LeukemiaHematologyCell BiologyStem Cells +2

KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570

A Chaix, Marie-Laure Arcangeli, S Lopez, +11

Oncogene

Kit-d816v Oncogenic ActivitySignal TransductionNatural SciencesMolecular BiologyCellular Biochemistry +3

The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability

William Grey, Adam Ivey, Thomas A. Milne, +5

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia

Magalí Sáez‐Ayala, Laurent Hoffer, Sébastien Abel, +19

Nature Communications